Abstract
The role of somatostatin (SS) receptor subtype 1 (SSTR1) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR1 agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR1 mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR1 receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR1, BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR 1 subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR1 may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.
Original language | English |
---|---|
Pages (from-to) | 142-148 |
Number of pages | 7 |
Journal | Neuroendocrinology |
Volume | 79 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2004 |
Keywords
- Acromegaly
- Clinical neuroendocrinology
- Growth hormone
- Insulin-like growth factors
- Somatostatin
- Somatostatin analogs
- Somatostatin receptors
ASJC Scopus subject areas
- Endocrinology
- Neuroscience(all)